https://www.thehindubusinessline.com/companies/generic-versions-of-novo-nordisks-semaglutide-begin-to-flow-priced-50-80-lower-than-the-innovator/article70769849.ece ...
The National Lok Adalat held across Bidar district resolved 66,440 cases through settlement, Senior Civil Judge and District Legal Services Authority Member-Secretary Prakash Arjun Bansode said on ...
A State-level Lok Adalat conducted across all courts in the State by the Karnataka State Legal Services Authority (KSLSA) on March 14 has reported settling over 55.85 lakh cases in a single day. The ...
Novo Nordisk is facing a massive wave of generic competitors to its injectable formulations of GLP-1 agonist semaglutide, used to treat diabetes and obesity, as a key patent in India is due to expire ...
Three Indian firms launched generic semaglutide after patent expiry for diabetes and obesity treatment Sun Pharma markets Noveltreat and Sematrinity with weekly costs from Rs 750 to Rs 2,000 Zydus ...
The simultaneous patent expiry of Ozempic’s active ingredient in China and India on Friday is a watershed moment. Until now, the revolutionary weight-loss drugs have been available largely to people ...
In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions. By Rebecca ...
Pharmaceutical companies have launched generic versions of Ozempic in India, beating Canadians to market despite the drugs being legal in Canada for nearly three months. Novo Nordisk’s remaining ...
DEALING WITH A DIFFICULT SITUATION, OR EVEN JUST BEFORE GOING HOME. A LOW COST ALTERNATIVE FOR COMMONLY USED ASTHMA MEDICATION WILL ENTER THE MARKET AFTER PRESSURE FROM SENATOR MAGGIE HASSAN ...
MUMBAI: Natco Pharma has heralded what could become an intense pricing war in India’s pharmaceutical sector by offering its generic version of semaglutide at 90% cheaper than the original weight-loss ...
Natco Pharma Ltd. is set to launch the generic version of Ozempic at a price that's 90% cheaper than the original created Novo Nordisk A/S, triggering a price war for weight-loss drugs in India as the ...
India is launching cheap weight-loss drugs — but Novo Nordisk is betting its brands will stay on top
Novo lost semaglutide patent protection in India, triggering generic launches. Indian drugmakers launched generic versions at lower prices. Novo cut prices and used partnerships to defend market share ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results